These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12243374)

  • 1. Do ancillary properties of antihypertensive drugs explain the outcome results of recent trials?
    Staessen JA; Wang J
    J Nephrol; 2002; 15(4):422-7. PubMed ID: 12243374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials.
    Staessen JA; Li Y; Thijs L; Wang JG
    Hypertens Res; 2005 May; 28(5):385-407. PubMed ID: 16156503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials.
    Wang JG; Staessen J
    J Clin Hypertens (Greenwich); 2003; 5(1):66-75. PubMed ID: 12556657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular protection and blood pressure reduction: a meta-analysis.
    Staessen JA; Wang JG; Thijs L
    Lancet; 2001 Oct; 358(9290):1305-15. PubMed ID: 11684211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs.
    Staessen JA; Thijs L; Li Y; Kuznetsova T; Richart T; Wang J; Birkenhäger WH
    Curr Opin Cardiol; 2007 Jul; 22(4):335-43. PubMed ID: 17556887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification for the prevention of cardiovascular complications of hypertension.
    Girerd X; Giral P
    Curr Med Res Opin; 2004 Jul; 20(7):1137-42. PubMed ID: 15265258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.
    Staessen JA; Wang JG; Thijs L
    J Hypertens; 2003 Jun; 21(6):1055-76. PubMed ID: 12777939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Are newer antihypertensive agents better than the older ones? Results of trials (CAPPP, STOP-2, NORDIL, INSIGHT and ALLHAT) with newer antihypertensive agents].
    Hildebrandt PR; Tuxen CD; Kjeldsen SE; Lund-Johansen P; Hansson L
    Ugeskr Laeger; 2001 Dec; 164(1):18-21. PubMed ID: 11810791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary and secondary prevention of stroke by antihypertensive drug treatment.
    Wang JG; Li Y
    Expert Rev Neurother; 2004 Nov; 4(6):1023-31. PubMed ID: 15853529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
    Wald DS; Law M; Morris JK; Bestwick JP; Wald NJ
    Am J Med; 2009 Mar; 122(3):290-300. PubMed ID: 19272490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ; Anderson S
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes in the comparative hypertension drug trials: more consensus than controversy.
    Ong HT
    Singapore Med J; 2008 Aug; 49(8):599-605; quiz 606. PubMed ID: 18756340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On-treatment diastolic blood pressure and prognosis in systolic hypertension.
    Fagard RH; Staessen JA; Thijs L; Celis H; Bulpitt CJ; de Leeuw PW; Leonetti G; Tuomilehto J; Yodfat Y
    Arch Intern Med; 2007 Sep; 167(17):1884-91. PubMed ID: 17893310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH
    Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulse pressure monitoring of open antihypertensive therapy.
    Safar ME; Vaisse B; Blacher J; Rudnichi A; Mourad JJ
    Am J Hypertens; 2004 Dec; 17(12 Pt 1):1088-94. PubMed ID: 15607613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.